학술논문

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
Document Type
article
Source
The Oncologist. 25(3)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Cancer
Rare Diseases
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Drug Labeling
Drug Prescriptions
Humans
Neoplasms
Pharmaceutical Preparations
Pilot Projects
United States
United States Food and Drug Administration
Drug prescriptions
Drug legislation
Drug approval
Pharmaceutical research
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.